Stoke Therapeutics Inc (NASDAQ:STOK) — Market Cap & Net Worth
Market Cap & Net Worth: Stoke Therapeutics Inc (STOK)
Stoke Therapeutics Inc (NASDAQ:STOK) has a market capitalization of $1.82 Billion ($1.82 Billion) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6627 globally and #1947 in its home market, demonstrating a -5.30% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Stoke Therapeutics Inc's stock price $33.08 by its total outstanding shares 57117150 (57.12 Million). Analyse STOK operating cash flow to see how efficiently the company converts income to cash.
Stoke Therapeutics Inc Market Cap History: 2019 to 2026
Stoke Therapeutics Inc's market capitalization history from 2019 to 2026. Data shows growth from $1.62 Billion to $1.89 Billion (3.82% CAGR).
Index Memberships
Stoke Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.08% | #163 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #708 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.11% | #104 of 263 |
Weight: Stoke Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Stoke Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Stoke Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
17.23x
Stoke Therapeutics Inc's market cap is 17.23 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.37 Billion | $3.00 Million | -$84.71 Million | 456.75x | N/A |
| 2022 | $527.19 Million | $12.40 Million | -$93.11 Million | 42.50x | N/A |
| 2023 | $300.44 Million | $8.78 Million | -$104.70 Million | 34.22x | N/A |
| 2024 | $630.00 Million | $36.55 Million | -$88.98 Million | 17.23x | N/A |
Competitor Companies of STOK by Market Capitalization
Companies near Stoke Therapeutics Inc in the global market cap rankings as of May 2, 2026.
Key companies related to Stoke Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Stoke Therapeutics Inc Historical Marketcap From 2019 to 2026
Between 2019 and today, Stoke Therapeutics Inc's market cap moved from $1.62 Billion to $ 1.89 Billion, with a yearly change of 3.82%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.89 Billion | +4.22% |
| 2025 | $1.81 Billion | +187.76% |
| 2024 | $630.00 Million | +109.70% |
| 2023 | $300.44 Million | -43.01% |
| 2022 | $527.19 Million | -61.53% |
| 2021 | $1.37 Billion | -61.26% |
| 2020 | $3.54 Billion | +118.68% |
| 2019 | $1.62 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Stoke Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.82 Billion USD |
| MoneyControl | $1.82 Billion USD |
| MarketWatch | $1.82 Billion USD |
| marketcap.company | $1.82 Billion USD |
| Reuters | $1.82 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Stoke Therapeutics Inc
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-… Read more